bioAffinity closes $4.8M public offering; Nasdaq compliance extension received

bioAffinity Technologies, Inc.

• Gross proceeds of $4.8M from sale of 1,921,761 shares/pre-funded warrants at $2.50/$2.493 per unit.
• After closing and warrant exercises, common shares outstanding total 3,100,402.
• 1-for-30 reverse stock split effective Sept 19; eliminated ~$4M in derivative liabilities.
• Company believes it regained compliance with Nasdaq minimum bid price and equity requirements; extension granted to Oct 2.
• Warrant amendments and exercises contributed ~$2.8M equity and ~$1.3M cash.